53 related articles for article (PubMed ID: 34816394)
21. Chitooligosaccharides-modified PLGA nanoparticles enhance the antitumor efficacy of AZD9291 (Osimertinib) by promoting apoptosis.
Hu X; Chen S; Yin H; Wang Q; Duan Y; Jiang L; Zhao L
Int J Biol Macromol; 2020 Nov; 162():262-272. PubMed ID: 32569688
[TBL] [Abstract][Full Text] [Related]
22. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Yuan M; Huang LL; Chen JH; Wu J; Xu Q
Signal Transduct Target Ther; 2019; 4():61. PubMed ID: 31871778
[TBL] [Abstract][Full Text] [Related]
23. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer.
Lu X; Liu S; Han M; Yang X; Sun K; Wang H; Mu H; Du Y; Wang A; Ni L; Zhang C
Int J Pharm; 2019 Apr; 560():126-135. PubMed ID: 30742982
[TBL] [Abstract][Full Text] [Related]
24. Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy.
Clemons TD; Singh R; Sorolla A; Chaudhari N; Hubbard A; Iyer KS
Langmuir; 2018 Dec; 34(50):15343-15349. PubMed ID: 30441895
[TBL] [Abstract][Full Text] [Related]
25. Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.
Vogel WH; Jennifer P
J Adv Pract Oncol; 2016; 7(7):723-735. PubMed ID: 29670808
[TBL] [Abstract][Full Text] [Related]
26. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
27. Brain metastases in patients with non-small cell lung cancer: the role of mutated-
Hsiao SH; Chou YT; Lin SE; Hsu RC; Chung CL; Kao YR; Liu HE; Wu CW
Oncotarget; 2017 Aug; 8(32):53405-53418. PubMed ID: 28881820
[TBL] [Abstract][Full Text] [Related]
28. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
[TBL] [Abstract][Full Text] [Related]
29. Non-small cell lung cancer: current treatment and future advances.
Zappa C; Mousa SA
Transl Lung Cancer Res; 2016 Jun; 5(3):288-300. PubMed ID: 27413711
[TBL] [Abstract][Full Text] [Related]
30. Three-dimensional culture systems in cancer research: Focus on tumor spheroid model.
Nath S; Devi GR
Pharmacol Ther; 2016 Jul; 163():94-108. PubMed ID: 27063403
[TBL] [Abstract][Full Text] [Related]
31. Cationic Liposome- Multi-Walled Carbon Nanotubes Hybrids for Dual siPLK1 and Doxorubicin Delivery In Vitro.
Pereira S; Lee J; Rubio N; Hassan HA; Suffian IB; Wang JT; Klippstein R; Ballesteros B; Al-Jamal WT; Al-Jamal KT
Pharm Res; 2015 Oct; 32(10):3293-308. PubMed ID: 26085038
[TBL] [Abstract][Full Text] [Related]
32. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors.
Edmondson R; Broglie JJ; Adcock AF; Yang L
Assay Drug Dev Technol; 2014 May; 12(4):207-18. PubMed ID: 24831787
[TBL] [Abstract][Full Text] [Related]
33. Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.
Trummer BJ; Iyer V; Balu-Iyer SV; O'Connor R; Straubinger RM
J Pharm Sci; 2012 Aug; 101(8):2763-76. PubMed ID: 22581704
[TBL] [Abstract][Full Text] [Related]
34. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Godin-Heymann N; Ulkus L; Brannigan BW; McDermott U; Lamb J; Maheswaran S; Settleman J; Haber DA
Mol Cancer Ther; 2008 Apr; 7(4):874-9. PubMed ID: 18413800
[TBL] [Abstract][Full Text] [Related]
35. Clonogenic assay of cells in vitro.
Franken NA; Rodermond HM; Stap J; Haveman J; van Bree C
Nat Protoc; 2006; 1(5):2315-9. PubMed ID: 17406473
[TBL] [Abstract][Full Text] [Related]
36. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Owens DE; Peppas NA
Int J Pharm; 2006 Jan; 307(1):93-102. PubMed ID: 16303268
[TBL] [Abstract][Full Text] [Related]
37. Stability of liposomal formulations in physiological conditions for oral drug delivery.
Taira MC; Chiaramoni NS; Pecuch KM; Alonso-Romanowski S
Drug Deliv; 2004; 11(2):123-8. PubMed ID: 15200011
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation.
Sawant SS; Patil SM; Shukla SK; Kulkarni NS; Gupta V; Kunda NK
Drug Deliv Transl Res; 2022 Oct; 12(10):2474-2487. PubMed ID: 34816394
[TBL] [Abstract][Full Text] [Related]
39. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.
Zhang Q; Liu H; Yang J
Front Endocrinol (Lausanne); 2022; 13():833929. PubMed ID: 35677717
[TBL] [Abstract][Full Text] [Related]
40. Acquired Resistance to Osimertinib in
Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
